David S.H. Bell

7.5k total citations · 2 hit papers
169 papers, 5.5k citations indexed

About

David S.H. Bell is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Molecular Biology. According to data from OpenAlex, David S.H. Bell has authored 169 papers receiving a total of 5.5k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Endocrinology, Diabetes and Metabolism, 35 papers in Cardiology and Cardiovascular Medicine and 34 papers in Molecular Biology. Recurrent topics in David S.H. Bell's work include Diabetes Treatment and Management (55 papers), Diabetes Management and Research (54 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (25 papers). David S.H. Bell is often cited by papers focused on Diabetes Treatment and Management (55 papers), Diabetes Management and Research (54 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (25 papers). David S.H. Bell collaborates with scholars based in United States, Spain and United Kingdom. David S.H. Bell's co-authors include James H. O’Keefe, Fernando Ovalle, Edison Gonçalves, Donald D. Hensrud, Michael F. Holick, John H. Lee, Janet B. McGill, George L. Bakris, Vivian Fonseca and Mary Ann Lukas and has published in prestigious journals such as JAMA, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

David S.H. Bell

161 papers receiving 5.2k citations

Hit Papers

Vitamin D Deficiency 2004 2026 2011 2018 2008 2004 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Vitamin D Deficiency
    2008 563 citations James H. O’Keefe, David S.H. Bell et al. profile →
  2. Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension
    2004 536 citations Janet B. McGill, David S.H. Bell et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David S.H. Bell United States 37 2.5k 1.5k 1.0k 914 809 169 5.5k
Ranganath Muniyappa United States 33 2.0k 0.8× 1.2k 0.8× 1.5k 1.5× 917 1.0× 1.5k 1.9× 85 6.5k
Dario Pitocco Italy 40 2.2k 0.9× 990 0.7× 983 1.0× 1.3k 1.4× 715 0.9× 203 5.7k
Richard J. MacIsaac Australia 46 2.8k 1.1× 1.1k 0.8× 783 0.8× 882 1.0× 595 0.7× 227 6.9k
Francine K. Welty United States 41 1.8k 0.7× 1.4k 1.0× 800 0.8× 2.1k 2.3× 649 0.8× 125 5.6k
Jill P. Crandall United States 39 2.4k 1.0× 855 0.6× 1.5k 1.4× 1.0k 1.1× 1.9k 2.4× 91 7.0k
Ivana Zavaroni Italy 39 2.7k 1.1× 1.1k 0.7× 996 1.0× 737 0.8× 1.5k 1.8× 112 5.4k
Giovambattista Desideri Italy 46 1.9k 0.8× 1.8k 1.2× 1.3k 1.2× 1.2k 1.3× 1.3k 1.6× 216 7.7k
Luís Henrique Santos Canani Brazil 39 1.8k 0.7× 1.1k 0.8× 1.3k 1.3× 786 0.9× 1.2k 1.5× 204 6.3k
Wayne Huey‐Herng Sheu Taiwan 44 3.0k 1.2× 1.5k 1.0× 1.8k 1.7× 1.4k 1.5× 1.3k 1.7× 372 8.1k
Evangelos Liberopoulos Greece 42 2.2k 0.9× 1.1k 0.8× 937 0.9× 2.3k 2.5× 603 0.7× 292 6.2k

Countries citing papers authored by David S.H. Bell

Since Specialization
Citations

This map shows the geographic impact of David S.H. Bell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David S.H. Bell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David S.H. Bell more than expected).

Fields of papers citing papers by David S.H. Bell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David S.H. Bell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David S.H. Bell. The network helps show where David S.H. Bell may publish in the future.

Co-authorship network of co-authors of David S.H. Bell

This figure shows the co-authorship network connecting the top 25 collaborators of David S.H. Bell. A scholar is included among the top collaborators of David S.H. Bell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David S.H. Bell. David S.H. Bell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bell, David S.H. & Terri Jerkins. (2025). Diabetic distal symmetric polyneuropathy: More than just “tingling in the feet”. Diabetes Obesity and Metabolism. 28(2). 817–825.
2.
Bell, David S.H.. (2024). All That Glistens Is not Gold: Neuropathy in Diabetic Patients May not Be Exclusively due to Diabetes. Endocrine Practice. 31(2). 266–267. 1 indexed citations
3.
Bell, David S.H. & Terri Jerkins. (2024). Diabetic Charcot neuroarthropathy: A threat to both limb and life. Diabetes Obesity and Metabolism. 27(1). 35–39. 3 indexed citations
4.
Bell, David S.H. & Terri Jerkins. (2024). The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through ‘stacking’ of drugs from different classes. Diabetes Obesity and Metabolism. 26(6). 2046–2053. 7 indexed citations
5.
Bell, David S.H. & Edison Gonçalves. (2020). Stroke in the patient with diabetes (Part 2) – Prevention and the effects of glucose lowering therapies. Diabetes Research and Clinical Practice. 164. 108199–108199. 7 indexed citations
6.
Bell, David S.H. & Edison Gonçalves. (2020). Why Do Falls and Lower Limb Fractures Occur More Frequently in the Diabetic Patient and How Can They Be Prevented?. Diabetes Therapy. 11(8). 1687–1694. 6 indexed citations
7.
Patil, Harshal, Firas Al Badarin, Salman Bhatti, et al.. (2012). Meta-Analysis of Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Risk in Type 2 Diabetes Mellitus. The American Journal of Cardiology. 110(6). 826–833. 126 indexed citations
8.
Lynch, Michael J., et al.. (2010). Prescribing Practices and Polypharmacy in Kitovu Hospital, Uganda. Research Portal (Queen's University Belfast). 13(3). 66–71. 3 indexed citations
9.
Bell, David S.H.. (2005). ‘Dead in bed syndrome – a hypothesis’. Diabetes Obesity and Metabolism. 8(3). 261–263. 16 indexed citations
10.
Bell, David S.H. & Janet B. McGill. (2005). Carvedilol versus metropolol in diabetic hypertensive patients. Cardiology in Review. 22(10). 12–15. 1 indexed citations
11.
Bell, David S.H.. (2004). Advantages of a third-generation β-blocker in patients with diabetes mellitus. The American Journal of Cardiology. 93(9). 49–52. 33 indexed citations
12.
Bell, David S.H.. (2003). Why I Initiate Therapy with Two Insulin Sensitizers in Patients with Type 2 Diabetes. Endocrine Practice. 9(1). 98–100. 7 indexed citations
13.
Bell, David S.H.. (2001). Drugs for cardiovascular risk reduction in the diabetic patient. Current Diabetes Reports. 1(2). 133–139. 5 indexed citations
14.
Bell, David S.H.. (2000). Should anti-glutamic acid decarboxylase antibody levels be determined in new-onset diabetes?. Endocrine Practice. 6(2). 214–216. 2 indexed citations
15.
Bell, David S.H. & Fernando Ovalle. (2000). Improved Glycemic Control with Use of Continuous Subcutaneous Insulin Infusion Compared with Multiple Insulin Injection Therapy. Endocrine Practice. 6(5). 357–360. 14 indexed citations
16.
Bell, David S.H.. (1998). University Group Diabetes Program—“Déjà Vu All Over Again”?. Endocrine Practice. 4(1). 64–65. 2 indexed citations
17.
Ito, Hiroshi, David S.H. Bell, Mimi Tamamori, et al.. (1997). CGRP and hypertrophy of cardiomyocytes. Heart and Vessels. 12. 15–17. 1 indexed citations
18.
Tanizawa, Yukio, Ken C. Chiu, Rachel C. Janssen, et al.. (1994). Variability of the pancreatic islet beta cell/liver (GLUT 2) glucose transporter gene in NIDDM patients. Diabetologia. 37(4). 420–427. 36 indexed citations
19.
Bell, David S.H.. (1994). El choque de las civilizaciones. 18(212). 59–61. 6 indexed citations
20.
Bell, David S.H.. (1991). Lower limb problems in diabetic patients. Postgraduate Medicine. 89(8). 237–244. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ranganath Muniyappa Breakdown of academic impact, for papers by Dario Pitocco Breakdown of academic impact, for papers by Richard J. MacIsaac Breakdown of academic impact, for papers by Francine K. Welty Breakdown of academic impact, for papers by Jill P. Crandall Breakdown of academic impact, for papers by Ivana Zavaroni Breakdown of academic impact, for papers by Giovambattista Desideri Breakdown of academic impact, for papers by Luís Henrique Santos Canani Breakdown of academic impact, for papers by Wayne Huey‐Herng Sheu Breakdown of academic impact, for papers by Evangelos Liberopoulos
Rankless by CCL
2026